CAT-09-833
/ Catalent
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 04, 2025
Catalent’s SMARTag ADC Pipeline and New Enhanced Conjugates Offering Featured at 16th World ADC San Diego
(Businesswire)
- "The company announced preclinical efficacy and tolerability data demonstrating the potential of CAT-09-833, a SMARTag ADC targeting MUC1, for the treatment of platinum-resistant ovarian cancer. The company also introduced SMARTag Enhanced Conjugates, a new class of ADCs that combines different payload types to benefit more patients by amplifying efficacy without compromising safety."
Platinum resistant • Preclinical • Ovarian Cancer
1 to 1
Of
1
Go to page
1